Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Suzanne R Hayman

Showing results (71-80 of 242) with videos related to

Pageof 25
Sort By:
The Lancet. Haematology|December 5, 2016
Once-weekly ofatumumab in untreated or relapsed Waldenström's macroglobulinaemia: an open-label, single-arm, phase 2 studyRichard R Furman, Herbert A Eradat, Christine G DiRienzo, et al.
Mayo Clinic Proceedings|February 7, 2021
Coagulation Abnormalities in Light Chain AmyloidosisNadine Abdallah, Eli Muchtar, Angela Dispenzieri, et al.
Blood Cancer Journal|December 6, 2022
Second- and third-line treatment strategies in multiple myeloma: a referral-center experienceSarah Goldman-Mazur, Alissa Visram, S Vincent Rajkumar, et al.
Mayo Clinic Proceedings|January 4, 2011
Recent improvements in survival in primary systemic amyloidosis and the importance of an early mortality risk scoreShaji K Kumar, Morie A Gertz, Martha Q Lacy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 15, 2012
Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurementsShaji Kumar, Angela Dispenzieri, Martha Q Lacy, et al.
Annals of Hematology|July 21, 2010
Asymptomatic immunoglobulin light chain amyloidosis (AL) at the time of diagnostic bone marrow biopsy in newly diagnosed patients with multiple myeloma and smoldering myeloma. A series of 144 cases and a review of the literatureSergio Siragusa, William Morice, Morie A Gertz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 23, 2013
Coexistent multiple myeloma or increased bone marrow plasma cells define equally high-risk populations in patients with immunoglobulin light chain amyloidosisTaxiarchis V Kourelis, Shaji K Kumar, Morie A Gertz, et al.
Blood|August 28, 2010
Serum immunoglobulin free light-chain measurement in primary amyloidosis: prognostic value and correlations with clinical featuresShaji Kumar, Angela Dispenzieri, Jerry A Katzmann, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 6, 2019
Outcomes of Patients with Light Chain Amyloidosis Who Had Autologous Stem Cell Transplantation with 3 or More Organs InvolvedAbdullah S Al Saleh, M Hasib Sidiqi, Eli Muchtar, et al.
American Journal of Hematology|October 8, 2008
A novel report of cig-FISH and cytogenetics in POEMS syndromeAlan H Bryce, Rhett P Ketterling, Morie A Gertz, et al.
Pageof 25

Showing results (71-80 of 242) with videos related to

Sort By:
Pageof 25
The Lancet. Haematology|December 5, 2016
Once-weekly ofatumumab in untreated or relapsed Waldenström's macroglobulinaemia: an open-label, single-arm, phase 2 studyRichard R Furman, Herbert A Eradat, Christine G DiRienzo, et al.
Mayo Clinic Proceedings|February 7, 2021
Coagulation Abnormalities in Light Chain AmyloidosisNadine Abdallah, Eli Muchtar, Angela Dispenzieri, et al.
Blood Cancer Journal|December 6, 2022
Second- and third-line treatment strategies in multiple myeloma: a referral-center experienceSarah Goldman-Mazur, Alissa Visram, S Vincent Rajkumar, et al.
Mayo Clinic Proceedings|January 4, 2011
Recent improvements in survival in primary systemic amyloidosis and the importance of an early mortality risk scoreShaji K Kumar, Morie A Gertz, Martha Q Lacy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 15, 2012
Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurementsShaji Kumar, Angela Dispenzieri, Martha Q Lacy, et al.
Annals of Hematology|July 21, 2010
Asymptomatic immunoglobulin light chain amyloidosis (AL) at the time of diagnostic bone marrow biopsy in newly diagnosed patients with multiple myeloma and smoldering myeloma. A series of 144 cases and a review of the literatureSergio Siragusa, William Morice, Morie A Gertz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 23, 2013
Coexistent multiple myeloma or increased bone marrow plasma cells define equally high-risk populations in patients with immunoglobulin light chain amyloidosisTaxiarchis V Kourelis, Shaji K Kumar, Morie A Gertz, et al.
Blood|August 28, 2010
Serum immunoglobulin free light-chain measurement in primary amyloidosis: prognostic value and correlations with clinical featuresShaji Kumar, Angela Dispenzieri, Jerry A Katzmann, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 6, 2019
Outcomes of Patients with Light Chain Amyloidosis Who Had Autologous Stem Cell Transplantation with 3 or More Organs InvolvedAbdullah S Al Saleh, M Hasib Sidiqi, Eli Muchtar, et al.
American Journal of Hematology|October 8, 2008
A novel report of cig-FISH and cytogenetics in POEMS syndromeAlan H Bryce, Rhett P Ketterling, Morie A Gertz, et al.
Pageof 25